Free Trial

Bicara Therapeutics (BCAX) Competitors

Bicara Therapeutics logo
$13.40 +0.30 (+2.29%)
Closing price 03/27/2025 04:00 PM Eastern
Extended Trading
$13.37 -0.03 (-0.22%)
As of 03/27/2025 04:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BCAX vs. ACAD, MOR, XENE, AMRX, RXRX, TWST, BHC, NAMS, HCM, and MLTX

Should you be buying Bicara Therapeutics stock or one of its competitors? The main competitors of Bicara Therapeutics include ACADIA Pharmaceuticals (ACAD), MorphoSys (MOR), Xenon Pharmaceuticals (XENE), Amneal Pharmaceuticals (AMRX), Recursion Pharmaceuticals (RXRX), Twist Bioscience (TWST), Bausch Health Companies (BHC), NewAmsterdam Pharma (NAMS), HUTCHMED (HCM), and MoonLake Immunotherapeutics (MLTX). These companies are all part of the "pharmaceutical products" industry.

Bicara Therapeutics vs.

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Bicara Therapeutics (NASDAQ:BCAX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, community ranking, profitability, analyst recommendations, valuation, risk, institutional ownership and media sentiment.

ACADIA Pharmaceuticals received 884 more outperform votes than Bicara Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Bicara Therapeutics an outperform vote while only 73.05% of users gave ACADIA Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
ACADIA PharmaceuticalsOutperform Votes
897
73.05%
Underperform Votes
331
26.95%
Bicara TherapeuticsOutperform Votes
13
100.00%
Underperform Votes
No Votes

In the previous week, ACADIA Pharmaceuticals had 8 more articles in the media than Bicara Therapeutics. MarketBeat recorded 16 mentions for ACADIA Pharmaceuticals and 8 mentions for Bicara Therapeutics. Bicara Therapeutics' average media sentiment score of 0.64 beat ACADIA Pharmaceuticals' score of 0.63 indicating that Bicara Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ACADIA Pharmaceuticals
7 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Bicara Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. 28.3% of ACADIA Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

ACADIA Pharmaceuticals has a net margin of 13.83% compared to Bicara Therapeutics' net margin of 0.00%. ACADIA Pharmaceuticals' return on equity of 25.83% beat Bicara Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
ACADIA Pharmaceuticals13.83% 25.83% 14.71%
Bicara Therapeutics N/A N/A N/A

Bicara Therapeutics has lower revenue, but higher earnings than ACADIA Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ACADIA Pharmaceuticals$957.80M2.99-$61.29M$1.3612.64
Bicara TherapeuticsN/AN/AN/AN/AN/A

ACADIA Pharmaceuticals currently has a consensus price target of $23.93, indicating a potential upside of 39.23%. Bicara Therapeutics has a consensus price target of $36.50, indicating a potential upside of 172.40%. Given Bicara Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Bicara Therapeutics is more favorable than ACADIA Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ACADIA Pharmaceuticals
0 Sell rating(s)
8 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.50
Bicara Therapeutics
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
3.13

Summary

ACADIA Pharmaceuticals beats Bicara Therapeutics on 9 of the 14 factors compared between the two stocks.

Remove Ads
Get Bicara Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for BCAX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BCAX vs. The Competition

MetricBicara TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$729.17M$6.91B$5.64B$8.06B
Dividend YieldN/A2.73%4.56%4.02%
P/E RatioN/A7.2023.1319.03
Price / SalesN/A226.00383.8993.17
Price / CashN/A65.6738.1634.64
Price / BookN/A6.476.944.33
Net IncomeN/A$141.90M$3.20B$247.06M
7 Day Performance2.37%-3.05%-2.32%-0.53%
1 Month Performance8.41%-4.63%3.07%-3.74%
1 Year PerformanceN/A-8.61%11.16%1.72%

Bicara Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BCAX
Bicara Therapeutics
N/A$13.40
+2.3%
$36.50
+172.4%
N/A$729.17MN/A0.0032Earnings Report
Upcoming Earnings
Analyst Forecast
News Coverage
ACAD
ACADIA Pharmaceuticals
4.1525 of 5 stars
$17.23
+2.6%
$24.00
+39.3%
-5.5%$2.87B$957.80M22.09510
MOR
MorphoSys
N/A$18.96
flat
N/AN/A$2.86B$238.28M-5.45730
XENE
Xenon Pharmaceuticals
2.4877 of 5 stars
$36.45
+3.1%
$57.38
+57.4%
-19.9%$2.79B$9.43M-12.93210
AMRX
Amneal Pharmaceuticals
3.458 of 5 stars
$8.89
+2.7%
$10.80
+21.5%
+35.1%$2.76B$2.79B-13.077,600Positive News
RXRX
Recursion Pharmaceuticals
2.2211 of 5 stars
$6.79
+1.6%
$8.25
+21.5%
-41.3%$2.73B$58.49M-4.44400Gap Down
TWST
Twist Bioscience
3.9343 of 5 stars
$44.94
+4.8%
$54.40
+21.1%
+20.6%$2.68B$330.19M-13.30990
BHC
Bausch Health Companies
3.5511 of 5 stars
$7.27
+1.5%
$7.42
+2.1%
-35.7%$2.67B$9.63B-60.5419,900Options Volume
News Coverage
NAMS
NewAmsterdam Pharma
2.1131 of 5 stars
$24.00
+0.5%
$43.33
+80.6%
-1.3%$2.64B$45.56M-9.234Short Interest ↑
HCM
HUTCHMED
1.6515 of 5 stars
$15.09
+0.7%
$19.00
+25.9%
-9.4%$2.63B$630.20M0.001,988Gap Down
MLTX
MoonLake Immunotherapeutics
2.1301 of 5 stars
$40.58
+1.1%
$80.50
+98.4%
-20.7%$2.60BN/A-31.462
Remove Ads

Related Companies and Tools


This page (NASDAQ:BCAX) was last updated on 3/28/2025 by MarketBeat.com Staff
From Our Partners